Fifty outpatients of newly diagnosed hypertension (NDH,with course of disease ≤ 3 months) and 50 patients with routinely revisit hypertension (RRH,with course of disease ≥ 1 year) were consecutively enrolled respectively from February 2010 to July 2010.They were asked to complete the Beck Depression Inventory (BDI),Spielberger State-Trait Anxiety Inventory (STAI) and the SF-36 questionnaire.The results showed that compared with the RRH group,the NDH group were more worried about being diagnosed as hypertension,dependence and side effects of antihypertensive drugs and complications of hypertension (all P ＜ 0.05).The NDH group displayed significantly higher level of anxiety compared with that of the RRH group (P ＜ 0.001).No significant differences were found in depression and 8 dimensions of SF-36 forms between two groups (P ＞ 0.05).The results indicated that patients of NDH have significant higher level of anxiety than that of RRH,they should be given more psychological intervention and appropriate health education.

Venetoclax,a BCL-2 inhibitor that induces apoptosis,is primarily employed to treat hematological malignancies and has been shown to substantially improve complete response(CR)in patients with acute myelogenous leukemia(AML).However,with the widespread clinical application of venetoclax,cases of acquired drug resistance have emerged.To address this issue,extensive research has been con-ducted to explore ferroptosis as an alternative programmed cell death pathway that reverses venetoclax resistance.This review discusses the potential mechanisms of acquired resistance to venetoclax in hematological malignancies,provides an overview of several crucial regu-latory pathways associated with abnormal energy metabolism-induced ferroptosis in tumor cells,and summarizes various approaches to modulate energy metabolism in tumor cells to alter ferroptosis and potentially reverse acquired resistance to venetoclax,ultimately guiding the clinical application of venetoclax.